<?xml version="1.0" encoding="ISO-8859-1"?>
<brand>
	<name>votrient</name> <!-- used for downloads -->
	<title><![CDATA[VOTRIENT]]></title>
	<colour><![CDATA[#ff6600]]></colour>
	<logo>votrient.png</logo>
	<rootVideo>brain_move_longer_1920.mov</rootVideo>
	<rootCaption>
		<copy><![CDATA[Discover how VOTRIENT is lighting up the world of oncology]]></copy>
	</rootCaption>
	
	<menu contentID="0">
		<!-- Advanced Renal Cell Carcinoma (aRCC) -->
		<item id="0" contentID="0"><![CDATA[ADVANCED RENAL CELL CARCINOMA (aRCC)]]></item>
			<item id="0.0" contentID="0"><![CDATA[COMPARZ STUDY DESIGN]]></item>
			<item id="0.1" contentID="0"><![CDATA[COMPARABLE EFFICACY TO SUBITINIB]]></item>
			<item id="0.2" contentID="0"><![CDATA[DIFFERENTIATED SAFETY PROFILE FROM SUBITINIB]]></item>
			<item id="0.3" contentID="0"><![CDATA[LOWER IMPACT ON QoL THAN SUNITINIB]]></item>
			<item id="0.4" contentID="0"><![CDATA[PISCES STUDY DESIGN]]></item>
			<item id="0.5" contentID="0"><![CDATA[PREFERRED OVER SUNITINIB IN THE PISCES STUDY]]></item>
		
		<!-- Advanced Soft Tissue Sarcoma (aSTS) -->
		<item id="1" contentID="0"><![CDATA[ADVANCED SOFT TISSUE SARCOMA (aSTS)]]></item>
			<item id="1.0" contentID="0"><![CDATA[PHASE III DATA IN SECOND-LINE aSTS]]></item>
			<item id="1.1" contentID="0"><![CDATA[PFS IMPROVEMENT VS. PLACEBO]]></item>
			<item id="1.2" contentID="0"><![CDATA[CONSISTENT BENEFIT ACCROSS SUBTYPES]]></item>
			<item id="1.3" contentID="0"><![CDATA[WELL-ESTABLISHED SAFETY PROFILE]]></item>
			<item id="1.4" contentID="0"><![CDATA[MAINTAINS HRQoL VS. PLACEBO]]></item>
			
		<!-- Once-Daily Oral Dosing -->
		<item id="2" contentID="0"><![CDATA[ONCE-DAILY ORAL DOSING]]></item>
		
		<!-- Prescribing Information -->
		<item id="3" contentID="0"><![CDATA[PRESCRIBING INFORMATION]]></item>
		
	</menu>
	
	<content>
		<content id="0" action="video-bg" videoID="votrient-root" cuePointSet="votrient-root" />
	</content>
	
	<videos>
		<video id="votrient-root" filename="brain_move_longer_1920.mov" loopInFrame="51" loopOutFrame="348" />
	</videos>
	
	<cuePointSets>
		<cuePointSet id="votrient-root">
			<cuePoint id="cue1" inFrame="60" outFrame="187" boxXY="49,272" boxWidth="298">
				<image>pills.png</image>
				<body><![CDATA[VOTRIENT IS AVAILABLE AS A 200MG AND 400MG TABLET]]></body>
				<footer>VOTRIENT. Summary of Product Characteristics</footer>
			</cuePoint>
		</cuePointSet>
	</cuePointSets>
</brand>